Tirzepatide is a 39-amino-acid modified peptide designed to mimic the action of two native incretin hormones, GIP and GLP-1. By simultaneously activating both receptor pathways, it addresses metabolic regulation through multiple mechanisms.

Its primary mechanism involves enhancing glucose-dependent insulin secretion from the pancreas while suppressing glucagon release. Furthermore, it is known to delay gastric emptying, which helps reduce food intake and promote a feeling of satiety. These combined actions result in significant improvements in glycemic control and substantial reductions in body weight.

With a long half-life of approximately 5 days, Tirzepatide is suitable for studies requiring sustained, long-acting receptor activation. It is widely investigated for its therapeutic potential in type 2 diabetes and obesity.

• CAS Number: 2023788-19-2